恒瑞医药(600276.SH)：SHR-4298注射液获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-4298 injection, which is expected to commence soon [1] Group 1 - SHR-4298 injection is a self-developed Class 1 therapeutic biological product by the company [1] - The product has demonstrated good anti-tumor activity in preclinical animal models [1] - SHR-4298 is intended for the treatment of advanced solid tumors [1]